AOH1996 for the Treatment of Refractory Solid Tumors

Official record

Identifier

NCT05227326

Recruiting locations

country

United States

Interventions studied

PCNA Inhibitor AOH1996

Lead sponsor

City of Hope Medical Center

Target enrolment

92 participants

Study type

INTERVENTIONAL

Phase

Phase 1

Status

Recruiting

First posted

Feb 7, 2022

Last updated on the registry

Jul 28, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

Informed Consent and Willingness to Participate

* 1\. Documented informed consent by the participant
* 2\. Willingness to permit study team to obtain and use archival tissue, if already existing

Age Criteria, Performance Status and Life Expectancy

* 3\. Age: ≥ 18 years
* 4\. ECOG performance status ≤ 2
* 5\. Life expectancy of \> 3 months

Nature of Illness and Treatment History \_\_6. Patients with solid tumors failing standard therapies or patients refusing standard treatments (exception: Part B NSCLC combination (EGFR TKI + AOH1996) cohort: patients with stable disease or better on EGFR TKI for at least 2 months)

Contraception

\_\_7. Agreement by females and males of childbearing potential\* to use an adequate method of birth control (hormonal contraception is inadequate) or abstain from heterosexual activity for the course of the study through 30 days after the last dose of study medication. See Appendix B for guidelines.

\- Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only).

Laboratory Criteria (to be performed within 14 days prior to Day 1)

* 8\. ANC ≥ 1,500/mm3
* 9\. Platelets ≥ 100,000/mm3 :
* 10\. Total serum bilirubin ≤ 1.5 x ULN
* 11\. AST =\< 1.5 x ULN or =\< 3 x ULN with liver metastases
* 12\. ALT =\< 1.5 x ULN or =\< 3 x ULN with liver metastases
* 13\. Creatinine clearance of ≥ 60 mL/min per 24 hour urine or the Cockcroft-Gault
* 14\. Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

Exclusion Criteria

Concomitant Medications/Therapies \_\_1. Dietary/herbal supplements

* 2\. Other investigational products or chemotherapy. Exception: EGFR TKI in the NSCLC expansion cohort is allowed.
* 3\. Warfarin
* 4\. Current or planned use of agents contraindicated for use with strong CYP3A4 inducers
* 5\. Strong inhibitors or inducers of CYP2C9
* 6\. Strong inhibitors or inducers of CYP3A

Other Illnesses and Conditions

* 7\. Issues with tolerating oral medication (e.g., inability to swallow pills, malabsorption issues, ongoing nausea or vomiting).
* 8\. Women who are or are planning to become pregnant or breastfeed
* 9\. Known allergy to any of the components within the study agents and/or their excipients.
* 10\. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years.
* 11\. Intercurrent or historic medical condition that increases subject risk in the opinion of the Investigator. Eligibility may be revisited for intercurrent medical conditions once resolution/recovery is deemed adequate by the investigator (e.g. recovery from major surgery, completion of treatment for severe infection).

Noncompliance

\_\_12. Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

\*\*Eligibility should be confirmed per institutional policies.

Indexed under

Pancreatic Cancer